Kliogest (Norethisterone Acetate, Estradiol)

Kliogest, a combined estrogen‑progestogen, is used in hormonal pathways related to contraception and hormone replacement therapy.

• Prevention of pregnancy: provides reliable oral contraception for women of reproductive age.
• Regulation of menstrual cycles: helps normalize cycle length and flow.
• Management of menopausal symptoms (hormone replacement therapy): alleviates vasomotor symptoms and prevents bone loss.

• Kliogest supplies exogenous estradiol and norethisterone acetate, which bind to estrogen and progesterone receptors respectively. This suppresses the hypothalamic‑pituitary‑ovarian axis, reducing LH and FSH secretion, thereby preventing ovulation and inducing endometrial changes that lower the chance of implantation.

Kliogest may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea or vomiting
• Breast tenderness or enlargement
• Headache or migraine
• Mood swings or irritability
• Weight gain or fluid retention
• Spotting or breakthrough bleeding

Serious or Rare Side Effects

• Deep vein thrombosis or pulmonary embolism
• Stroke or myocardial infarction
• Severe hypertension
• Liver dysfunction or jaundice
• Allergic reactions such as rash, angioedema, or anaphylaxis

Before prescribing Kliogest, clinicians should evaluate individual risk factors and contraindications.

• Thromboembolic risk: avoid in patients with a history of clotting disorders.
• Cardiovascular disease: assess for hypertension, coronary artery disease, or stroke.
• Liver disease: use with caution in hepatic impairment.
• Smoking: discourage use in women over 35 who smoke.
• Pregnancy: contraindicated; ensure effective contraception.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Kliogest can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce hormonal levels.
• Anticoagulants (e.g., warfarin) where estrogen may increase clotting risk.

Moderate Interactions (Monitor Closely)

• Antiepileptic drugs (e.g., phenytoin) that may modestly lower contraceptive effectiveness.
• Certain antibiotics (e.g., metronidazole) that can increase estrogen exposure.
• Herbal supplements containing St. John's wort.
• Selective serotonin reuptake inhibitors that may exacerbate mood changes.